These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7034047)

  • 1. Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure.
    Packer M; Le Jemtel TH
    Prog Cardiovasc Dis; 1982; 24(4):275-92. PubMed ID: 7034047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasodilators in the management of acute heart failure.
    Elkayam U; Janmohamed M; Habib M; Hatamizadeh P
    Crit Care Med; 2008 Jan; 36(1 Suppl):S95-105. PubMed ID: 18158484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. Advocacy of a pragmatic approach to the selection of a therapeutic agent.
    Packer M
    Am J Med; 1984 Jun; 76(6A):3-13. PubMed ID: 6377886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydralazine in heart failure.
    Chatterjee K
    Herz; 1983 Aug; 8(4):187-98. PubMed ID: 6413340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs.
    Packer M; Meller J; Medina N; Yushak M
    Am J Cardiol; 1981 Aug; 48(2):375-9. PubMed ID: 6791486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of vasodilator, inotropic or combined therapy for the management of heart failure.
    Cohn JN; Franciosa JA
    Am J Med; 1978 Jul; 65(1):181-8. PubMed ID: 685992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of vasodilator therapy in heart failure.
    Chatterjee K; Parmley WW
    Prog Cardiovasc Dis; 1977; 19(4):301-25. PubMed ID: 401541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
    Mason DT
    Am J Med; 1978 Jul; 65(1):106-25. PubMed ID: 99030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination vasodilator therapy for severe chronic congestive heart failure.
    Chatterjee K; Drew D; Parmley WW; Klausner SC; Polansky J; Zacherle B
    Ann Intern Med; 1976 Oct; 85(4):467-70. PubMed ID: 823852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
    Chatterjee K; Massie B; Rubin S; Gelberg H; Brundage BH; Ports TA
    Am J Med; 1978 Jul; 65(1):134-45. PubMed ID: 99031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs.
    Packer M; Medina N; Yushak M
    Am Heart J; 1982 Nov; 104(5 Pt 2):1215-23. PubMed ID: 6753552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
    Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy.
    Packer M; Meller J; Medina N; Yushak M; Gorlin R
    Am J Cardiol; 1981 Nov; 48(5):939-46. PubMed ID: 7304442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of vasodilators and long-term response in heart failure.
    Franciosa JA; Dunkman WB; Leddy CL
    J Am Coll Cardiol; 1984 Jun; 3(6):1521-30. PubMed ID: 6325522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic and metabolic effects of vasodilator therapy for heart failure in acute myocardial infarction.
    Kodama K; Koretsune Y; Nanto S; Taniura K
    Jpn Circ J; 1984 Apr; 48(4):380-7. PubMed ID: 6425527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasodilator and inotropic therapy of heart failure [panel discussion].
    Am J Med; 1978 Jul; 65(1):208-16. PubMed ID: 685996
    [No Abstract]   [Full Text] [Related]  

  • 17. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
    Kessler PD; Packer M; Medina N; Yushak M
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hemodynamic responses to vasodilator therapy in congestive heart failure.
    Ribner HS; Bresnahan D; Hsieh AM; Silverman R; Tommaso C; Coath A; Askenazi J
    Prog Cardiovasc Dis; 1982; 25(1):1-42. PubMed ID: 6287524
    [No Abstract]   [Full Text] [Related]  

  • 19. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function.
    Capomolla S; Pozzoli M; Opasich C; Febo O; Riccardi G; Salvucci F; Maestri R; Sisti M; Cobelli F; Tavazzi L
    Am Heart J; 1997 Dec; 134(6):1089-98. PubMed ID: 9424070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasodilators as first-line therapy for congestive heart failure: a comparative hemodynamic study of hydralazine, digoxin, and their combination.
    Ribner HS; Zucker MJ; Stasior C; Talentowski D; Stadnicki R; Lesch M
    Am Heart J; 1987 Jul; 114(1 Pt 1):91-6. PubMed ID: 3604877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.